West Pharmaceutical Services (MEX:WST) EBIT: MXN12,301 Mil (TTM As of Mar. 2026)


MEX:WST West Pharmaceutical Services Inc MEX:WST
95 GF Score
Price MXN5,112.51
GF Value MXN5,334.68
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services EBIT?

West Pharmaceutical Services MEX:WST 95 EBIT is MXN12,301 Mil as of Mar. 2026. GuruFocus rates MEX:WST with a GF Score™ of 95/100 and a GF Value™ of MXN5,334.68. The stock has 9 warning signs investors should review.

West Pharmaceutical Services's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN3,282 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN12,301 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. West Pharmaceutical Services's annualized ROC % for the quarter that ended in Mar. 2026 was 17.85%. West Pharmaceutical Services's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 29.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. West Pharmaceutical Services's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.87%.


West Pharmaceutical Services  (MEX:WST) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

West Pharmaceutical Services's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=13062.888 * ( 1 - 24.82% )/( (53428.314 + 56586.613)/ 2 )
=9820.6791984/55007.4635
=17.85 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=76884.339 - 9208.115 - ( 14247.91 - max(0, 11791.933 - 35618.876+14247.91))
=53428.314

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=74110.791 - 8121.928 - ( 9402.25 - max(0, 12154.04 - 32942.136+9402.25))
=56586.613

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

West Pharmaceutical Services's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=13127.804/( ( (33191.707 + max(9987.762, 0)) + (32682.466 + max(11771.746, 0)) )/ 2 )
=13127.804/( ( 43179.469 + 44454.212 )/ 2 )
=13127.804/43816.8405
=29.96 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10342.474 + 7992.73 + 3035.762) - (9208.115 + 934.496 + 1240.593)
=9987.762

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12363.219 + 8161.6 + 3015.067) - (8121.928 + 0 + 3646.212)
=11771.746

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

West Pharmaceutical Services's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=12301.374/428011.735
=2.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


West Pharmaceutical Services EBIT Related Terms


West Pharmaceutical Services EBIT Historical Data

* Premium members only.

The historical data trend for West Pharmaceutical Services's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services EBIT Chart

West Pharmaceutical Services Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,531.15 13,409.35 12,000.79 12,273.58 10,828.63

West Pharmaceutical Services Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,268.81 2,958.07 3,157.04 2,904.32 3,281.95

MEX:WST vs RMD, MDLN, SOLV: EBIT Comparison

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


West Pharmaceutical Services EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's EV-to-EBIT falls into.


MEX:WST
95GF Score
West Pharmaceutical Services Inc MEX:WST
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

West Pharmaceutical Services EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN12,301 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN12,301 Mil mean?
West Pharmaceutical Services (MEX:WST) has a EBIT of MXN12,301 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on West Pharmaceutical Services.
Is West Pharmaceutical Services' EBIT too high?
West Pharmaceutical Services' current EBIT is MXN12,301 Mil. Overall, West Pharmaceutical Services has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' EBIT compare to RMD and MDLN?
West Pharmaceutical Services' EBIT of MXN12,301 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on West Pharmaceutical Services. West Pharmaceutical Services's current EBIT is MXN12,301 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
West Pharmaceutical Services (MEX:WST) has a current EBIT of MXN12,301 Mil. The stock's GF Value™ is MXN5,334.68, compared to a current price of MXN5,112.51 — trading 4.2% below its estimated fair value. The current EBIT is MXN12,301 Mil. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For West Pharmaceutical Services (MEX:WST), the current EBIT is MXN12,301 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (MEX:WST) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued. The current stock price of MXN5,112.51 is trading 4.2% below its estimated GF Value™ of MXN5,334.68.

Key valuation signals for MEX:WST:

  • EBIT: MXN12,301 Mil
  • GF Value™: MXN5,334.68 vs. price of MXN5,112.51 (4.2% below fair value)
  • GF Score™: 95/100 with 9 warning signs

No single metric tells the full story. See the MEX:WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score

Get the complete analysis for MEX:WST

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN5,112.51
Price
MXN5,334.68
GF Value